Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Berchuck

Showing results (51-60 of 372) with videos related to

Pageof 38
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)|February 18, 2011
Reduction of ovarian and oviductal cancers in calorie-restricted laying chickensDonna K Carver, H John Barnes, Kenneth E Anderson, et al.
American Journal of Obstetrics and Gynecology|May 1, 2004
Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarraysAndrew Berchuck, Edwin S Iversen, Johnathan M Lancaster, et al.
Gynecologic Oncology|May 8, 2007
Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group studyAngeles Alvarez Secord, Kathleen M Darcy, Alan Hutson, et al.
Gynecologic Oncology|December 25, 2012
Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American womenDelores J Grant, Cathrine Hoyo, Lucy Akushevich, et al.
Gynecologic Oncology|September 1, 2020
Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancerRafael Gonzalez, Laura J Havrilesky, Evan R Myers, et al.
The Lancet. Oncology|August 3, 2011
Association between KRAS rs61764370 and triple-negative breast cancer--a false positive?Paul Pharoah, Antonis Antoniou, Andrew Berchuck, et al.
Cancer|January 22, 2011
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reductionLaura J Havrilesky, Gillian D Sanders, Shalini Kulasingam, et al.
International Journal of Cancer|January 3, 2014
Epigenetic determinants of ovarian clear cell carcinoma biologyKen Yamaguchi, Zhiqing Huang, Noriomi Matsumura, et al.
Gynecologic Oncology|June 22, 2007
Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomasJay E Allard, John I Risinger, Carl Morrison, et al.
Obstetrics and Gynecology|June 24, 2009
Evaluation of two management strategies for preoperative grade 1 endometrial cancerMarcus Q Bernardini, Taymaa May, Mahmoud A Khalifa, et al.
Pageof 38

Showing results (51-60 of 372) with videos related to

Sort By:
Pageof 38
Cancer Prevention Research (Philadelphia, Pa.)|February 18, 2011
Reduction of ovarian and oviductal cancers in calorie-restricted laying chickensDonna K Carver, H John Barnes, Kenneth E Anderson, et al.
American Journal of Obstetrics and Gynecology|May 1, 2004
Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarraysAndrew Berchuck, Edwin S Iversen, Johnathan M Lancaster, et al.
Gynecologic Oncology|May 8, 2007
Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group studyAngeles Alvarez Secord, Kathleen M Darcy, Alan Hutson, et al.
Gynecologic Oncology|December 25, 2012
Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American womenDelores J Grant, Cathrine Hoyo, Lucy Akushevich, et al.
Gynecologic Oncology|September 1, 2020
Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancerRafael Gonzalez, Laura J Havrilesky, Evan R Myers, et al.
The Lancet. Oncology|August 3, 2011
Association between KRAS rs61764370 and triple-negative breast cancer--a false positive?Paul Pharoah, Antonis Antoniou, Andrew Berchuck, et al.
Cancer|January 22, 2011
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reductionLaura J Havrilesky, Gillian D Sanders, Shalini Kulasingam, et al.
International Journal of Cancer|January 3, 2014
Epigenetic determinants of ovarian clear cell carcinoma biologyKen Yamaguchi, Zhiqing Huang, Noriomi Matsumura, et al.
Gynecologic Oncology|June 22, 2007
Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomasJay E Allard, John I Risinger, Carl Morrison, et al.
Obstetrics and Gynecology|June 24, 2009
Evaluation of two management strategies for preoperative grade 1 endometrial cancerMarcus Q Bernardini, Taymaa May, Mahmoud A Khalifa, et al.
Pageof 38